Evgen is based in Liverpool, at the Liverpool Science Park and was founded in 2007 by Dr Stephen Franklin.
Evgen is a clinical stage drug development company whose lead programmes are in cancer and subarachnoid haemorrhage (a type of stroke). It is also carrying out preclinical work in relapsing remitting multiple sclerosis.
Evgen’s core technology is Sulforadex®, a novel, synthetic and stabilised version of the naturally occurring compound sulforaphane. Sulforaphane is an established anti-cancer agent that benefits from a huge amount of peer-reviewed scientific literature identifying both its anti-cancer and neuroprotective characteristics. However, its commercial development as a potential prescription medicine has been prevented by the instability of the compound. Evgen’s Sulforadex® technology overcomes this problem by creating a stable version of sulforaphane, which can be delivered as a tablet or capsule.
The potential of Sulforadex® has allowed Evgen to attract a highly experienced commercial, scientific and advisory team. The company is led by Chief Executive Dr Stephen Franklin, who has a track record in the commercialisation of intellectual property, and Chairman Barry Clare, the former director of the Boots Company plc and head of its Boots Healthcare International business.